MULTIVALVE : A Prospective Multicentre Study of Multiple and Mixed Valvular Heart Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-10-31

Study Completion Date

2032-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Multiple and mixed valvular heart disease (MMVD) is a common condition in clinical practice. It corresponds to a combination of stenotic or leaky lesions on two or more heart valves (multiple valve disease), or a combination of stenotic and leaky lesions on the same valve (mixed valve disease). However, the management of their clinical, biological and cardiovascular imaging is not well established. Current European Society of Cardiology (ESC) recommendations primarily address the various valve diseases in isolation. This results in an absence of reliable recommendations for managing MMVD, with different approaches being adopted by care centres.

In order to address this knowledge gap regarding MMVD, it is crucial to assess its prevalence, the cardiovascular imaging methods employed and the management strategies, as well as to identify prognostic factors for the various combinations of valve disease.

The multicentre MMVD study will be a valuable resource as it will improve our understanding of the prognosis for patients with MMVD. It will highlight imaging and biological markers associated with the prognosis of different combinations of MMVD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study

NCT06235385

Heart Valve Diseases Multiple Valve Disease, Unspecified Aortic Valve Disease +11 more

RECRUITING

Outcomes in Moderate Mixed Aortic Valve Disease

NCT06789211

Mixed Aortic Valve Disease

RECRUITING

Filling Pressures of the Left Ventricle in Patients With Significant Aortic Stenosis

NCT01727310

Valvular Disease

COMPLETED

Retrospective Prospective Multicentric Clinical Follow up of Patients After Being Treated With TricValve®

NCT05114850

Tricuspid Regurgitation Tricuspid Valve Insufficiency Tricuspid Insufficiency +3 more

RECRUITING

A Multicentre Retrospective Study on Bicuspid Aortic Valve

NCT05818722

Bicuspid Aortic Valve

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

National, Prospective, Multicentric Registry. Patients with a diagnosis of MMVD identified by echocardiography will be included and followed up at 1, 2, 3 and 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Valvular Heart Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with a diagnosis of MMVD

Patients with a diagnosis of MMVD based on cardiovascular imaging and defined as follows:

At least two cases of moderate to severe valvular heart disease, as assessed by a cardiologist and defined by transthoracic echocardiography (TTE) on one or more valves. This is in line with the recommendations of the European Society of Cardiology (ESC), the American Society of Echocardiography (ASE) and expert opinion.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥18 years
* The patient has been informed of the study and has not refused to participate.
* An echocardiographic diagnosis of MMVD is defined as having at least two moderate to severe valvulopathies, as assessed by a cardiologist using transthoracic echocardiography (TTE), on one or more valves. This is in line with the recommendations of the ESC, the ASE, and expert opinion.

Exclusion Criteria

* History of valve surgery or percutaneous valve intervention involving the valve in question.
* A history of infective endocarditis, whether treated surgically or not, confirmed according to the modified Duke criteria.
* Acute infective endocarditis at the time of evaluation for inclusion, confirmed according to the modified Duke criteria.
* Complex congenital heart disease.
* Patients who are already included in the European EACVI-MMVD study.
* Pregnant women
* Patients not affiliated to social security
* Patients who are minors
* Patients under guardianship, curatorship or judicial supervision
* Patients who refuse to participate in this register.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No